HOME / Notice / News / EN
NKCL Bio Group, which has consistently contributed to the advancement of the bio industry in South Korea, including enhancing the nation’s competitiveness through innovative management activities, has been awarded the 2023 National Empathy Campaign ‘R&D Management’ sector. The group stated tha...
NKCL Bio Group announced on the 31st that it has obtained both CE certification and KC certification on the 27th for ‘RK-NKTM ACS (hereinafter referred to as ACS-I)’, an automatic single-person NK cell cultivator released this year. CE certification is an integrated standard certification mark mean...
NKCL Bio Group Inc. won the grand prize in the NK cell therapy category at the 17th ‘Korea Health Industry Awards’ in 2023 The Korea Health Industry Award, which provides an opportunity to spread awareness about the importance of the health industry, raises its status, and boosts morale in the heal...
NKCL Bio Group announced that it had recently acquired a patent for a stimulant composition for rapid testing of natural killer cell activity and a test method using the same. Ph.D. Shin Dong-hyeok of NKCL Bio Group said, “Normally, NK cells in our body are inactive, but they are activated and respo...
NKCL Bio Group Inc. won the ‘2023 Customer Love Brand Grand Prize’ in the immune care platform category. |Growing into a global top bio company in the K-Bio field through immune care platform services On May 16th, NKCL Bio Group Inc., a bio company that researches and develops NK immune cell therap...